ischemic stroke
Conditions
Interventions
treatment group:Breviscapine dripping pills, 8 pills, 3 times a day
Ginkgo biloba leaf simulator, 2 tablets, 3 times a day.
control group:Ginkgo leaf, 2 pieces at a time, 3 times a day
Breviscapine dripping pills simulator, 8 pills, 3 times a day
Sponsors
The Third Affiliated Hospital of Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. It is consistent with the recovery period of TCM apoplexy (middle meridian and collaterals), and the syndrome differentiation is blood stasis blocking collaterals; 2. It meets the diagnostic criteria of Western medicine for ischemic stroke (cerebral infarction) and is proved to be ischemic stroke by imaging; 3. Aged 40-80 years old (including the critical value); 4. 2 weeks to 3 months after onset of ischemic stroke (including the critical value); 5. Light and medium patients with neurological impairment degree score 6 <= NIHSS <= 20; 6. Patients with first onset or previous stroke without obvious sequelae (mRS Score <= 1 before the onset of the disease); 7. Volunteer to participate in the trial and sign an informed consent before the study begins.
Exclusion criteria
Exclusion criteria: 1. Patients with other brain diseases confirmed by head CT or MRI, such as cerebral hemorrhage, brain tumor, brain trauma, transient ischemic attack (TIA), hemorrhagic infarction; 2. Patients with severe disturbance of consciousness affecting the evaluation of outcome efficacy indicators; 3. Allergic constitution, allergic to the test drug or its related ingredients; 4. Hypotension, systolic 185 mmHg or diastolic blood pressure > 110 mmHg; 5. Patients with severe diabetes mellitus, liver and kidney damage, ALT and AST levels were 1.5 times higher than the normal value, Cr was higher than the normal value; 6. Patients with other complications and complications that affect drug evaluation, such as severe cardiac insufficiency, renal insufficiency, severe mental illness, cerebral hemorrhage after cerebral infarction, etc.; 7. Patients with other diseases affecting limb movement and function, patients with limb movement dysfunction caused by claudication, osteoarthritis, rheumatoid arthritis, gouty arthritis before treatment, which may affect neurological function examination; 8. Patients with bleeding tendency or severe bleeding within 3 months; 9. Patients who were unable to complete daily activities independently due to various diseases and physical weakness before the disease had serious impact on the efficacy evaluation; 10. Pregnant and lactating women, pregnancy test positive or recent family planning; 11. Participants are participating in other clinical trials or participating in other drug clinical trials within 3 months; 12. Other situations considered by the researchers to be inappropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Rankin Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| National Institutes of Health Stroke Scale;Barthel index;Adverse events; | — |
Countries
China
Contacts
Public ContactSun Wenjun
The Third Affiliated Hospital of Beijing University of Chinese Medicine
Outcome results
None listed